Abstract: The present invention relates to novel covalent oligo and polyalkylene glycol conjugates with synthetic inhibitors of trypsin-type serine proteases, in particular inhibitors of the hemocoagulation protease thrombin, synthetic intermediates stages required in their production and their use for producing active ingredients for the treatment or prophylaxis of thrombotic complications.
Abstract: The invention relates to a method for determining the total clotting activity of a blood or plasma sample, characterized in that a highly specific, not irreversible thrombin inhibitor is added to a blood or plasma sample in a defined amount, the clotting of the blood or plasma sample is induced and, after a defined period of time, the consumed amount of the added thrombin inhibitor is determined in a per se known manner, as well as to a kit for obtaining information about the state of coagulation of a blood sample.
Abstract: The invention relates to a blood-compatible surface comprising a polymer surface and a plurality of conjugates made of linkers and active agents immobilized thereon. The polymer surface contains similar or different structural units that carry carbonyl groups. The linkers contain a structural element that is able to form a hydrogen bridge bond. A polyorganosiloxane acting as the active agent is linked to the linkers.
Abstract: The invention relates to a method for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid. It comprises the following steps. The body liquid is taken from a living body, and the body liquid is subjected to a separation from the turbid matter, if necessary. To the non-turbid body liquid thus obtained are added a coagulation-inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., a chromogenic or fluorogenic substrate not dissociable by active meizothrombin or Mtdesfgl, resp., and a substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., and as an optional prothrobmin. The thus obtained solution or mixture, resp., is subjected to a wavelength-selective light absorption or light emission measurement as a function of the time.
Abstract: The present invention relates to novel covalent oligo and polyalkylene glycol conjugates with synthetic inhibitors of trypsin-type serine proteases, in particular inhibitors of the hemocoagulation protease thrombin, synthetic intermediates stages required in their production and their use for producing active ingredients for the treatment or prophylaxis of thrombotic complications.
Abstract: The present invention relates to a process for separating substances, which are bonded to a polymer surface via a linker, by adding a polar organic solvent.